



GLINT: GlucoCEST IMAGING IN NEOPLASTIC TUMOURS

The EU-funded project GLINT aims to develop and bring to the clinic a potentially disruptive new diagnostic tool and a set of technologies for in vivo cancer imaging which can characterise and image glucose delivery, uptake and metabolism in cancer.

The GLINT project addresses the current global lack of safe, cheap, easily accessible and accurate image-based metabolic evaluation techniques to detect cancer and will develop an innovative method which will allow for more accurate, less invasive, more reliable and earlier cancer diagnosis.

The GLINT consortium is made up of a multidisciplinary team of eight partners from leading research institutions and industry from in- and outside the European Union. Their joint expertise combines toxicology, biochemistry, chemistry, physics, engineering and image processing together with regulatory, clinical and commercial know-how. As a group, they pursue their common goal of providing an inexpensive, widely available, more comprehensive, non-invasive and radiation-free method complementing nuclear medicine techniques currently used for cancer assessment within Europe.

The GLINT project builds on recent research revealing the sensitivity of a technique named glucose-based chemical exchange saturation transfer (glucoCEST) to detect native (D-glucose) glucose uptake in tumours and that glucose analogues, such as 3-oxy-methyl-D-glucose (3OMG), can be used as potential non-metabolisable tracers using the same technique.

The project intends to bring the combination of native D-glucose and 3-O-methyl-D-glucose as a combined exam to European clinical oncology practice to assess cancer glucose uptake and metabolism in almost all cancer types, thereby providing a wide-ranging new diagnostic tool for one of the most devastating diseases in the world.

The impressive potential of the GLINT proposal ensured that the project emerged highly successful in the face of the particularly competitive selection process for the last health call under the EU Research and Innovation programme Horizon 2020.

For more information contact GLINT's project manager Katharina Krischak at kkrischak@eibir.org.

FUNDING

January 2016 – December 2019
Horizon 2020

€6,454,612

CONSORTIUM

University College London, UK
(coordinator)

EIBIR, AT

Tel Aviv University, IL

University of Torino, IT

Max Planck Society, DE

University of Zurich, CH

Olea Medical, FR

Bracco Imaging, IT



@GLINT_H2020

EIBIR | EUROPEAN INSTITUTE
FOR BIOMEDICAL
IMAGING RESEARCH

